University of Tokyo and Amplo Biotechnology sign Exclusive License Agreement for patent applications to advance novel DOK7 gene therapy for neuromuscular diseases

Summary

University of Tokyo today announced the signing of an Exclusive License Agreement for patent applications with Amplo Biotechnology, a new adeno-associated virus (AAV) gene Therapy Company, to develop an AAV expressing DOK7 gene for the treatment of several neuromuscular diseases.

Content:

Professor Yuji Yamanashi of the Institute of Medical Science at the University of Tokyo an inventor of the DOK7 gene therapy, notes that loss of neuromuscular junction function leads to the loss of motor function including breathing and swallowing. His research group previously identified DOK7 as an essential protein for neuromuscular junction formation. This group, in collaboration with Professor David Beeson's group of University of Oxford, has also identified a neuromuscular junction disorder caused by abnormalities in DOK7 gene: DOK7 myasthenia (references 1, 2). In mice, systemic administration of an AAV expressing DOK7 gene (AAV-D7) has shown therapeutic benefit in models of DOK7 myasthenia, Emery-Dreifuss Muscular Dystrophy and Amyotrophic Lateral Sclerosis (references 3, 4).

Amplo Biotechnology identified the potential of DOK7 to significantly improve the life of many patients suffering from neuromuscular disorders. Amplo believes that "The data sets for DOK7 myasthenia and for ALS are impressive, significantly increasing survival in mouse models of these devastating diseases. We at Amplo, are excited to move the therapy forward for the benefit of patients."

The University of Tokyo wishes to acknowledge research support from a Grant-in-Aid of the Translational Research Network Program from the Ministry of Education, Culture, Sports, Science and Technology of Japan and a Grant-in-Aid for Scientific Research on Innovative Areas and the Practical Research Project for Rare/Intractable Diseases from the Japan Agency for Medical Research and Development.

Contact at The University of Tokyo:
Professor Yuji Yamanashi
The Institute of Medical Science, The University of Tokyo
TEL : +81-3-6409-2115 | Email : yyamanas@ims.u-tokyo.ac.jp

About Amplo Biotechnology
Amplo is a gene therapy company focused on developing novel AAV therapies for rare neurodegenerative and neuromuscular disorders.

References:

1) Okada K, Inoue A, Okada M, Murata Y, Kakuta S, Jigami T, Kubo S, Shiraishi H, Eguchi K, Motomura M, Akiyama T, Iwakura Y, Higuchi O and Yamanashi Y. The muscle protein Dok-7 is essential for neuromuscular synaptogenesis. *Science* 312:1802-1805 (2006)

2) Beeson D, Higuchi O, Palace J, Cossins J, Spearman H, Maxwell S, Newsom-Davis J, Burke G, Fawcett P, Motomura M, Muller JS, Lochmuller H, Slater C, Vincent A and Yamanashi Y. Dok-7 mutations underlie a neuromuscular junction synaptopathy. *Science* 313:1975-1978 (2006)

3) Arimura S, Okada T, Tezuka T, Chiyo T, Kasahara Y, Yoshimura T, Motomura M, Yoshida N, Beeson D, Takeda S, and Yamanashi Y: *DOK7* gene therapy benefits mouse models of diseases characterized by defects in the neuromuscular junction. Science 345:1505-1508 (2014)

4) Miyoshi S, Tezuka T, Arimura S, Tomono T, Okada T, and Yamanashi Y. DOK7 gene therapy enhances motor activity and life span in ALS model mice. *EMBO Mol. Med.* 9:880-889 (2017)